Skip to search formSkip to main contentSkip to account menu

gemcabene

Known as: 6,6'-oxybis(2,2-dimethylhexanoic acid) 
A dialkyl ether dicarboxylic acid with antihyperlipidemic activity. In animal models gemcabene increased high density lipoprotein (HDL) cholesterol… 
National Institutes of Health

Related topics

Related topics

3 relations

Narrower (2)

CI-1027PD 72953

Broader (1)

Caproates

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Gemcabene, a First-in-Class Hypolipidemic Small Molecule in Clinical Development, Attenuates Osteoarthritis and Pain in Animal Models of Arthritis and Pain
Our clinical studies have demonstrated that gemcabene, a small molecule in late-stage clinical development, lowers pro… 
2018
2018
Gemcabene Regulates VLDL-remnant Trafficking and Inflammation Genes with Potential Impact on Cardiovascular Disease
2017
2017
EFFECT OF GEMCABENE ON INSULIN SENSITIVITY IN NONDIABETIC, OBESE SUBJECTS
2016
2016
Gemcabene combination for the treatment of cardiovascular disease
The present invention provides a formulated to include statins and gemcabene pharmaceutical composition, wherein the composition… 
2016
2016
Abstract 229: Correlation of in vitro Studies and Human Drug Interaction Studies with Gemcabene
Background: Gemcabene is a novel lipid-regulating compound being developed as an adjunct to diet and statin therapy for… 
2015
2015
Abstract 17824: Gemcabene and Atorvastatin Alone and Combined Markedly Reduce LDL-C in LDL Receptor-deficient Mice, a Model of Homozygous Familial Hypercholesterolemia
Background: Gemcabene (Gem) is a late-stage Phase 2 clinical candidate being evaluated for the reduction of low-density… 
2015
2015
Abstract 13654: Gemcabene Monotherapy and in Combination With Atorvastatin Lowers High Sensitivity C-Reactive Protein (hsCRP) in a Phase 2 Clinical Trial
Background: It is well established that inflammation plays a key role the progression of atherosclerosis and that serum high… 
Highly Cited
2007
Highly Cited
2007
Limited influence of UGT1A1*28 and no effect of UGT2B7*2 polymorphisms on UGT1A1 or UGT2B7 activities and protein expression in human liver microsomes.
AIMS UGT1A1 and UGT2B7 are enzymes that commonly contribute to drug glucuronidation. Since genetic factors have been suggested to… 
2005
2005
UDP-GLUCURONOSYLTRANSFERASE 2B7 IS THE MAJOR ENZYME RESPONSIBLE FOR GEMCABENE GLUCURONIDATION IN HUMAN LIVER MICROSOMES
The predominant metabolic pathway of gemcabene in humans is glucuronidation. The principal human UDP-glucuronosyltransferases… 
2005
2005
Strategies to Improve Model-based Decision-making During Clinical Development
Objectives: To assess the utility of a novel PK/PD-based modeling and simulation strategy as well as the utility of the Pharsight… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)